FSD Pharma Inc. - Class B Subordinate Voting Shares (NQ:HUGE)

0.0899 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FSD Pharma Inc. - Class B Subordinate Voting Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

FSD Pharma Inc. Board Approves Share Repurchase Program ↗

December 30, 2021

FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is repurchasing up to 2 million company shares. The...

Via Benzinga

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program

December 30, 2021

Via Investor Brand Network

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program

December 30, 2021

Via Investor Brand Network

FSD Pharma Announces Share Repurchase Program

December 30, 2021

From FSD Pharma Inc.

Via Business Wire

Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S. ↗

December 28, 2021

Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

FSD Pharma Announces Establishment of Advisory Board, Strategic Appointments ↗

December 23, 2021

FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory...

Via Benzinga

FSD Pharma Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating ↗

December 23, 2021

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data...

Via Benzinga

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS

December 23, 2021

Via Investor Brand Network

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments

December 23, 2021

Via Investor Brand Network

FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members

December 09, 2021

From FSD Pharma Inc.

Via Business Wire

FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

December 03, 2021

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)

December 02, 2021

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish

November 16, 2021

From FSD Pharma Inc.

Via Business Wire

Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention

October 27, 2021

Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...

Via FinancialNewsMedia

FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH

October 19, 2021

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

September 22, 2021

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

September 21, 2021

From FSD Pharma Inc.

Via Business Wire

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold ↗

August 30, 2021

Contents

Via Benzinga

Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals ↗

August 25, 2021

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:

Via Benzinga

FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm ↗

August 25, 2021

FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related: See Why FSD Pharma...

Via Benzinga

54 Biggest Movers From Yesterday ↗

August 26, 2021

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently...

Via Benzinga

36 Stocks Moving In Wednesday's Mid-Day Session ↗

August 25, 2021

Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR...

Via Benzinga

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

August 25, 2021

From FSD Pharma Inc.

Via Business Wire

See Why FSD Pharma Terminated COVID-19 Trial ↗

August 25, 2021

FSD Pharma Inc (NASDAQ: HUGE) will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19. FSD-201 works by...

Via Benzinga

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug ↗

August 25, 2021

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

21 Stocks Moving in Wednesday's Pre-Market Session ↗

August 25, 2021

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported...

Via Benzinga

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

August 24, 2021

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause

July 27, 2021

From FSD Pharma Inc.

Via Business Wire

64 Biggest Movers From Friday ↗

June 07, 2021

Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM...

Via Benzinga

40 Stocks Moving In Friday's Mid-Day Session ↗

June 04, 2021

Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday. Senseonics Holdings, Inc. (NYSE: SENS) gained 26% to $2.5817 after the...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.